Tonix Pharmaceuticals Holding Corp. has released a presentation detailing their current developments in therapeutics for pain, neurologic, psychiatric, and addiction conditions, as well as other areas of high unmet need such as immunology and infectious disease. The company is focused on a central nervous system portfolio and is advancing several investigational new drugs or biologics. Notably, TNX-102 SL, a sublingual tablet aimed at treating fibromyalgia, has been granted Fast Track Designation by the FDA, with a target goal date for marketing authorization set for August 15, 2025. Additionally, Tonix is working on a range of other products, including medications for acute stress disorder, organ transplant rejection, and cancer, among others. These efforts are supported by strategic partnerships with government institutions and academic organizations. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.